Tom Ellsworth
@bizdocpodcast·63.4K subscribers·1.6K videos
Sanofi Buys Blueprint Medicines for $9.1 Billion
Posted
June 3, 2025
Views
1,381
Likes
42
Comments
5
Engagement
3.40%
June 3, 2025
1,381
42
5
3.40%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
1:26Now PlayingSanofi has announced its acquisition of US-based Blueprint Medicines for approximately $9.1 billion in cash, with the total deal value potentially reaching $9.5 billion if certain clinical and regulatory milestones are met. The transaction, the largest European pharma deal of 2025, involves a $129 per share cash payment, reflecting a 27% premium over Blueprint's recent closing price. Through the deal, Sanofi acquires Blueprint’s FDA-approved Ayvakit, currently the only treatment for advanced systemic mastocytosis, and access to its early-stage immunology pipeline. This move strengthens Sanofi's portfolio in immunology and rare diseases and aligns with its strategic focus on the US market and innovation. Industry analysts predict strong future sales for Ayvakit and see the acquisition as reinforcing Sanofi’s commitment to R&D.
Sign up to VTNews
Subscribe to VTNews
_________________________________
Watch The Biz Doc Podcast every Friday at 1pm & catch a new "Biz Doc Bite" every single day at 9:30am EST.
Thanks for watching! And I hope I left you better than I found you.
Subscribe to the channel and turn on notifications!
_________________________________
FaceTime or Ask Tom Ellsworth any questions on
Help us welcome back Tom Ellsworth! Follow him on social media:
#BizDoc #BusinessInsider #Valuetainment #Business #News
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
